Accomplished business and operational leaders join leader in diabetes data management
MOUNTAIN VIEW, Calif., February 13, 2020 — As part of its continued global expansion, Glooko, the leader in diabetes digital health and data management solutions, today announced the appointment of Zach Henderson as Chief Commercial Officer and Komathi Stem as Chief Operating Officer. Henderson joins Glooko with extensive executive background at healthcare data and analytics companies leading a range of commercial functions, from alliance management and portfolio strategy to sales, marketing, and revenue generation. Stem comes to Glooko having served in a wide range of leadership roles in the life science industry with a focus on the use of real-world data and digital technologies to transform and accelerate clinical trials.
“We’re pleased to have Komathi and Zach joining us now as we expand our offerings to help the global healthcare ecosystem better understand and manage diabetes and support health care providers managing their patient populations using our data, analytics, and clinical research solutions,” said Russ Johannesson, CEO of Glooko. “The year ahead holds tremendous potential for Glooko and having the depth of business and leadership experience that Zach and Komathi bring will be a major advantage as we look forward to significantly increasing our positive impact in the diabetes community.”
In his new role with Glooko, Henderson will have global responsibility for all commercial efforts, including the company’s work with its key strategic partners and revenue generation initiatives.
“As the leader in diabetes data management, Glooko is integrated with more diabetes and health devices than any other platform in the world, creating an opportunity to provide extensive insights. We have a unique opportunity to improve the lives of those with diabetes by leveraging the global Glooko data platform to advance research and the treatment of patients,” said Henderson. “I’m excited to be joining the Glooko team as it transitions to its next phase of growth.”
Henderson comes to Glooko from LexisNexis Health Care and Elsevier, where he served as vice president of strategy, alliances and data sourcing and was responsible for the creation and development of a strategic alliance program of go-to-market and enablement partners, the negotiation of strategic partnership deals, and the integration of new business acquisitions. Prior to LexisNexis, he served in a range of senior commercial leadership roles at healthcare data and analytics companies, including Health Market Science and IMS Health (now IQVIA). Henderson earned an MBA from Villanova University.
In her new role as COO of Glooko, Stem will have global responsibility for Glooko product development, clinical research, and customer support.
In her previous role, Stem was founder and CEO of monARC Bionetworks, a health data collection and analytics company aimed at modernizing clinical research by empowering patients to share their real-world data generated from routine care and digital tools so it can be transformed into real-world evidence that accelerates research and improves care.
“Glooko’s mission to empower people with diabetes to use their data to improve care and contribute real-world data to advance research is completely aligned with my passion to transform research and care using the growing body of real-world data,” Stem said. “I’m pleased to be joining the Glooko team as we continue leading the way in turning integrated diabetes data into actionable insights for people with diabetes and their providers.”
Prior to monARC Bionetworks, Stem has led the transformation of clinical trials via her leadership roles at Science 37, Genentech, AstraZeneca, Amgen and Eli Lilly. She holds a Master of Science degree in biomedical engineering from the University of Virginia.
About Glooko
Glooko’s universal diabetes software products provide insights to improve outcomes for people with diabetes and their care teams. The Glooko product suite contains the Glooko and diasend® diabetes management solutions, which integrate with many of the leading EHR systems used today. Both systems synchronize data from more than 190 diabetes devices and activity trackers, and they deliver integrated, timely and useful patient data, including glucose levels, blood pressure, weight, and food, insulin and medication intake. Trusted by the world’s leaders in diabetes care, our solutions cover more than 2.2 million people with diabetes and are used in 9,000+ clinic locations in 24 countries across 15 languages. Learn more by visiting www.glooko.com
Media Contacts
Robin Beadle
Glooko
[email protected]
Jeff Christensen
SignalWest Public Relations
+1 831-566-0275
[email protected]
Recognition of a Significant Milestone in Larger Data Protection Program of Diabetes Data Management Pioneer
MOUNTAIN VIEW, Calif., Dec. 11, 2019 /PRNewswire/ — Glooko®, the global leader in diabetes data management, today announced it has received Privacy Shield certification from the U.S. Department of Commerce. This official recognition verifies the company has taken specific steps to ensure the protection of consumers’ personal data when transferring it from Europe to the U.S. and has committed to the Privacy Shield Principles, which are intended to protect against the misuse and unwarranted collection of personally-identifying patient information.
In an era of well-publicized consumer data breaches, data privacy and security is a major concern for internet users and has become a growing problem across the board in business. The healthcare industry, in fact, has become particularly susceptible to cyberattacks, and at an average cost of $6.45 million per breach of patient data, health care has the highest average cost per breach of all U.S. business sectors, according to this year’s “Cost of a Data Breach Report” from IBM and the Ponemon Institute. Recent U.S. healthcare data breaches have been attributed to a range of causes, including hacking, IT incidents, and theft, loss, improper disposal, and unauthorized access or disclosure of patient records.
To add to it, the number of breaches in health care continues to increase. After reaching a record high once in 2018 and twice more early this year for the number of data breaches in a single month, U.S. healthcare organizations reached an all-time high yet again in July, reporting a total of 50 data breaches, the most reported in a single month since the HHS Office for Civil Rights established its online database of healthcare breaches in 2010.
That’s why Glooko is especially pleased to have the chance to help lead the way in Privacy Shield certification for diabetes device and data management companies, as only about 10 percent of such companies have pursued and achieved the certification to date.i Even still, the company believes certification must be about more than compliance.
“We’re grateful for Privacy Shield certification and that the mechanism is there to help with compliance. Nevertheless, Glooko has set an internal standard that goes beyond just meeting the minimum requirements regarding data laws,” said Russ Johannesson, CEO of Glooko. “Managing diabetes requires gathering and handling a lot of personal data, and because we believe people with diabetes own their data and protecting their privacy comes first, earning their trust and that of their healthcare providers is our real objective. That far surpasses simply staying inside the lines.”
Privacy Shield was created by the Commerce Department, the European Commission, and the Swiss Administration, and it was activated in 2016. To earn certification, a U.S. company is required to conduct a self-certification process for the Commerce Department and publicly commit to comply with the Privacy Shield Principles. And while Privacy Shield certification is voluntary for U.S. companies, once an eligible company commits to comply with the requirements, the commitment becomes enforceable under U.S. law.
Glooko is proud to have earned the Privacy Shield certification, but it’s a milestone that supports just one part of the larger three-part data protection program that the company is implementing and has made a focus of how it operates. First, Glooko has made a formal declaration of its values regarding data ethics and patient rights via the development and adoption of its Data Ethics Policy, which serves as a guiding light for how the company and its employees will handle health data. It has also gone to great lengths to author and establish its data privacy policies, formalizing them through official certifications like Privacy Shield. And the most rigorous part of Glooko’s program is its actual safeguarding of the data managed on its platform through installing strong security controls, a demanding process being validated by Glooko’s pursuit of the industry-driven seal of approval known as HITRUST Certification.
“As people with diabetes and clinics are managing billions of data points on the Glooko platform, we’re at ‘center stage’ in today’s digital diabetes landscape,” said Melissa Liu, Glooko’s Senior Director of Operations, Privacy & Security. “In light of that pivotal role in handling so much sensitive data, our uncompromising efforts should reassure anyone working with us that Glooko is trustworthy and committed to data protection, from patients and providers to healthcare systems and the device companies with whom we partner.”
About Glooko
Glooko’s universal diabetes software products provide insights to improve outcomes for people with diabetes and their care teams. The Glooko product suite contains the Glooko and diasend® diabetes management solutions, which integrate with many of the leading EHR systems used today. Both systems synchronize data from more than 190 diabetes devices and activity trackers, and they deliver integrated, timely and useful patient data, including glucose levels, blood pressure, weight, and food, insulin and medication intake. Trusted by the world’s leaders in diabetes care, our solutions cover more than 2.2 million people with diabetes and are used in 9,000+ clinic locations in 24 countries across 15 languages. Learn more by visiting www.glooko.com
Media Contacts:
Holly McGarraugh
Glooko
510-282-2852
Jeff Christensen
SignalWest Public Relations
+1 831-566-0275
Milestone verifies digital health leader’s commitment to ensuring quality and safety of its products
MOUNTAIN VIEW, Calif., Dec. 10, 2019 /PRNewswire/ — Glooko®, the global leader in diabetes data management, announced today that its Mountain View, California and Gothenburg, Sweden sites have received joint ISO 13485:2016 certification from accredited certification body Intertek Testing Services NA Ltd. This certification demonstrates Glooko’s commitment to establishing a compliant quality management system and following practices and procedures that meet customer, safety and regulatory requirements applicable to medical devices. It verifies for regulators, strategic partners, and the diabetes community that Glooko is committed to ensuring the quality and safety of its digital health products and services.
ISO 13485 is an International Organization for Standardization (ISO) standard that describes the requirements for comprehensive practices and procedures for the design, development, production, and delivery of medical devices, including digital health software. To become ISO 13485 certified, Glooko underwent thorough evaluations of its corporate quality management system via a Stage 1 pre-certification audit in June 2019 and Stage 2 certification audits in September 2019 (Mountain View) and October 2019 (Gothenburg), with zero Stage 2 nonconformities noted.
“Organizations in the medical device industry are required to demonstrate their quality management processes and ensure they’re following regulations and standards for developing safe and reliable products,” said Russ Johannesson, CEO of Glooko. “Our certification to ISO 13485 is an important milestone that confirms our quality management system has met internationally-recognized requirements, and that Glooko is committed to ongoing compliance and improvement.”
Because digital health products like Glooko must comply with regulatory standards that meet the quality, safety and clinical needs of people with diabetes and their providers, quality management in digital health is about more than simply developing and testing software.
“Being certified to the ISO 13485 standard is especially important because digital health software is more than a tech product—it is a healthcare product with global quality and safety requirements,” said Mary Beth McDonald, senior director of regulatory and quality management for Glooko.
Beyond regulatory compliance, ISO 13485 certification demonstrates the robustness of Glooko’s quality management system to the Food and Drug Administration (FDA), European Union, and Glooko’s strategic partners.
About Glooko
Glooko’s universal diabetes software products provide insights to improve outcomes for people with diabetes and their care teams. The Glooko product suite contains the Glooko and diasend® diabetes management solutions, which integrate with many of the leading EHR systems used today. Both systems synchronize data from more than 190 diabetes devices and activity trackers, and they deliver integrated, timely and useful patient data, including glucose levels, blood pressure, weight, and food, insulin and medication intake. Trusted by the world’s leaders in diabetes care, our solutions cover more than 2.2 million people with diabetes and are used in 9,000+ clinic locations in 24 countries across 15 languages. Learn more by visiting www.glooko.com
Media Contacts:
Holly McGarraugh
Glooko
510-282-2852
Jeff Christensen
SignalWest Public Relations
+1 831-566-0275
[email protected]
New third-party app connections, more compatible devices and in-clinic Bluetooth uploads to better connect patients and their data with clinicians
MOUNTAIN VIEW, California/US and GOTHENBURG, Sweden, 17 September 2019 — Glooko®, the leader in diabetes data management solutions, continues to strengthen its global position with the introduction of several new features and expanded connectivity capabilities for the diasend® by Glooko system at this week’s 55th annual meeting of the European Association for the Study of Diabetes (EASD). The additional device integration partnerships, new ways to upload patient data in clinic, and feature enhancements will be unveiled at the September 17-20 meeting in Barcelona.
Increased device compatibility
At EASD, Europe’s largest and most prominent diabetes meeting, Glooko will share new device integrations it has developed with two new partners:
- Ypsomed’s mylife™ YpsoPump® Insulin Pump* is now compatible with diasend® via app connection to mylife™ Cloud. By linking the two systems together, data flows between them seamlessly and automatically and is easily accessible for both patients and clinicians.
- Basal insulin data from Tandem Diabetes Care’s t:slim X2™ – with Basal-IQ® technology can now be viewed in diasend® by uploading it at home or during a clinic consultation along with information from other diabetes devices, then reviewing it in customizable charts, graphs and tables.
Additional ways to upload data in-clinic
At the beginning of 2019, NFC connectivity (near-field communication) was introduced in the hardware of the diasend® by Glooko system, which serves as a “one-stop shop” for patients when visiting their health care provider, because it’s able to upload data from numerous devices regardless of brand. Now, BLE (Bluetooth Low Energy) is also added to the mix of ways to upload data to the diasend® solution, providing greater flexibility for the upload process and making clinic/patient interaction even easier. Both NFC and BLE are expected to become increasingly common in diabetes devices during the next couple of years.
“Glooko is pleased to bring additional value to our customers with new data solutions and device integrations on our trusted diasend data management platform,” said Russ Johannesson, CEO of Glooko. “It exemplifies the increasing momentum of Glooko solutions, which provide comprehensive patientbased diabetes data to physicians, better connecting them with their patients. Our greater reach with diasend by Glooko enables healthcare professionals to better focus on value-based outcomes for the patients they serve.”
Prominent speakers at EASD
On the scientific front, Glooko will offer in-booth presentations from two renowned speakers:
- Professor Roman Hovorka (University of Cambridge) will present on the topic of how the use of closed-loop systems in diabetes management has become increasingly common, which highlights the importance of using an integrated diabetes management system to handle and draw conclusions from data uploads.
- Dr. Dominic Ehrmann (Diabetes Center Mergentheim) will present the results from a multicenter randomized controlled trial, where diasend by Glooko was used to evaluate an education programme of flash glucose monitoring.
“We are proud of the array of diasend by Glooko news that will be showcased at EASD this year, and how it highlights our continuous innovation. We are adding more options to our comprehensive list of compatible devices and introducing new ways for them to function seamlessly with our universal solution,” said Anders Sonesson, Global VP and General Manager of Glooko. “As always, we put our users at the heart of everything we do, and these additions will facilitate the patient/clinic interaction from both sides.”
*Available in selected European countries.
About Glooko
Glooko’s universal diabetes software products provide insights to improve outcomes for people with diabetes and their care teams. The Glooko product suite contains the Glooko and diasend® diabetes management solutions, which integrate with many of the leading EHR systems used today. Both systems synchronize data from more than 190 diabetes devices and activity trackers, and they deliver integrated, timely and useful patient data, including glucose levels, blood pressure, weight, and food, insulin and medication intake. Trusted by the world’s leaders in diabetes care, our solutions cover more than 2.2 million people with diabetes and are used in 9,000+ clinic locations in 24 countries across 15 languages. Learn more by visiting www.glooko.com
Media Contacts:
Sebastian Persson
Marketing Director EMEA/APAC
[email protected]
+46 701 46 10 10
Jeff Christensen
SignalWest Public Relations
+1 831-566-0275
[email protected]
Accomplished finance and operations leader brings deep experience in SaaS and healthcare technology to continue acceleration of diabetes data management leader’s growth
MOUNTAIN VIEW, Calif., July 16, 2019—Glooko®, the global leader in diabetes data management solutions, today announced the appointment of Stephen Lien as Chief Financial Officer. Lien comes to Glooko with relevant and extensive experience serving in senior leadership roles in finance and operations across a range of related industries. Some of these include healthcare technology, consumer software, enterprise software, digital media, and software as a service (SaaS). Glooko serves healthcare providers, payers and people with diabetes through its leading FDA-cleared, HIPAA-compliant diabetes management platform.
“We’re very excited to have a seasoned finance and operations executive of Steve’s caliber joining the Glooko team, especially at this stage in our company’s development,” said Russ Johannesson, CEO of Glooko. “Steve is a leader with a strong track record for not only accelerating revenue and maximizing returns but also for scaling global businesses and taking them to the next level, and most recently, that has been with organizations focused on SaaS solutions in the healthcare space.”
Lien comes to Glooko having served most recently as CFO of PipelineRx, a healthcare SaaS technology company that provides pharmacy solutions to inpatient and outpatient pharmacies. Responsible for leading the finance, pharmacy operations, HR and compliance functions at PipelineRx, Lien managed the company’s transformation from a tech-enabled services provider to a technology SaaS subscription company. He also led the company in a Series F Growth Equity round of funding that raised $18 million from strategic investors and $15 million through debt financing, and he was instrumental in growing the company’s recurring annual contract value (ACV) more than 250 percent, year over year.
Prior to PipelineRx, Lien successfully served as CFO at several other companies, including Smart Tuition and SmartCare, a holding company for two SaaS providers (one in the K-12 education space and the other in child care services), where he provided strategic and financial advice leading to the sale of Smart Tuition to Blackbaud for $190 million. Prior to that, as CFO of Skrill Limited—Moneybookers, Inc., a leader in e-commerce and digital payments, Lien built the financial foundation in the U.S. that enabled the sale of the company to CVC Partners for €600 million.
Lien is particularly enthusiastic to be coming to Glooko, where he can continue his work in healthcare technology.
“The global Glooko platform and database have grown into one of the largest in diabetes, serving more than 2.2 million people with diabetes, connecting them with their health care providers and generating powerful insights that are helping guide treatment decisions,” Lien said. “I’m excited to be joining Russ and the rest of the Glooko team in accelerating that growth and scaling the company as we strive to serve more payers, providers, and people with diabetes.”
Lien holds a bachelor’s degree in economics and business administration from the University of California, Berkeley’s Haas School of Business.
About Glooko
Glooko’s universal diabetes software products provide insights to improve outcomes for people with diabetes and their care teams. The Glooko product suite contains the Glooko and diasend® diabetes management solutions, which integrate with many of the leading EHR systems used today. Both systems synchronize data from more than 190 diabetes devices and activity trackers, and they deliver integrated, timely and useful patient data, including glucose levels, blood pressure, weight, and food, insulin and medication intake. Trusted by the world’s leaders in diabetes care, our solutions cover more than 2.2 million people with diabetes and are used in 9,000+ clinic locations in 23 countries across 15 languages. Learn more by visiting www.glooko.com.
Media contact:
Holly McGarraugh
Glooko
510-282-2852
Jeff Christensen
SignalWest Public Relations
831-566-0275
SAN DIEGO and MOUNTAIN VIEW, Calif., June 5th, 2019 – Companion Medical, a leader in the development of advanced insulin delivery technology to improve diabetes care, and Glooko, a leader in diabetes data visualization and management, have announced an integrated data partnership agreement that will enable insulin data from users of the InPen™ Smart Insulin Injection Pen to be integrated into the Glooko® Enterprise diabetes data management system and Glooko® Mobile App. This integration, through Apple Health, will allow users to automatically integrate their insulin data with the Glooko diabetes data management system for clinical evaluation by their healthcare professionals.
“We are thrilled to be working with Glooko to bring integrated multiple daily injection (MDI) insulin data into the Glooko system,” said Companion Medical’s Chief Executive Officer Sean Saint. “Our mission is to bring insulin data together with glucose and other contextual data in a way that is seamless, easy and automatic for both healthcare professionals and their patients. Our partnership with Glooko is an important step in that mission.”
The announcement of this integration is significant because InPen is the first “smart” insulin pen to introduce its data integration and compatibility with the Glooko platform in the U.S. More than 70 percent of the 7.4 million insulin users in the U.S. take their insulin via MDI, and of those, approximately half take it using an insulin pen.
“We are excited to launch support for InPen on the Glooko platform,” said Russ Johannesson, CEO of Glooko. “InPen is an innovative solution for calculating insulin doses and tracking insulin injection data. We feel users will get tremendous value out of seeing this data correlated with the food, activity, and glucose information in Glooko to help them make informed treatment decisions when they dose and see diabetes insights and trends over time that may not have been previously known.”
The partnership allows people living with diabetes who use InPen to integrate their multiple daily injection regimen data, both long-acting and rapid-acting, into the Glooko diabetes data platform.
“We believe this is a huge step forward in the development of integrated diabetes management because it allows data never seen before, both long and short-acting insulin, to be integrated with other diabetes data residing in the Glooko platform without the need for downloading or manually entering data,” said Companion Medical’s Chief Technology Officer Mike Mensinger.
InPen is available in the U.S. by prescription only. The Glooko Mobile App is available for free download in the Apple Store and Android Play.
For more information, visit www.companionmedical.com and www.glooko.com.
About Companion Medical
Companion Medical is a leader in the development of advanced technology to improve diabetes care. InPen™, the first and only FDA-cleared smart insulin pen, combines an innovative diabetes management app with a Bluetooth® enabled pen injector to simplify the constant tracking, monitoring and calculating required for insulin therapy. InPen addresses many of the issues that people living with diabetes face on a daily basis, including missed insulin doses, miscalculated insulin doses and insulin stacking.
About Glooko
Glooko’s universal diabetes software products provide insights to improve outcomes for people with diabetes and their care teams. The Glooko product suite contains the Glooko and diasend® diabetes management solutions, which integrate with many of the leading EHR systems used today. Both systems synchronize data from more than 190 diabetes devices and activity trackers, and they deliver integrated, timely and useful patient data, including glucose levels, blood pressure, weight, and food, insulin and medication intake. Trusted by the world’s leaders in diabetes care, our solutions cover more than 2.2 million people with diabetes and are used in 9,000 clinic locations in 23 countries across 15 languages. Learn more by visiting www.glooko.com.
Media contact:
Companion Medical
Amanda Sanders, MBA
Senior Manager of Marketing
858-522-0252 ext. 6342
www.companionmedical.com
Glooko
Jeff Christensen
SignalWest Public Relations
831-566-0275
Leading endocrinologist recognized as an expert in diabetes data analytics brings broad patient care and clinical research experience to diabetes data management leader
MOUNTAIN VIEW, Calif., May 21, 2019 — Glooko, the leader in diabetes data management solutions, today announced the appointment of Mark Clements, MD, PhD, CPI, FAAP, as Chief Medical Officer. Dr. Clements joins the senior management team of Glooko having served on its medical advisory board since it was formed in 2015 to provide expertise to the organization in the areas of clinical studies and diabetes analytics.
Dr. Clements comes to Glooko from the University of Missouri-Kansas City School of Medicine, where he is Associate Professor of Pediatrics. He is also a pediatric endocrinologist at Children’s Mercy Kansas City, where he serves as Director of Pediatric Endocrine/Diabetes Clinical Research and Medical Director for the Pediatric Clinical Research Unit. He will continue his work with the medical school and Children’s Mercy as he also takes on his new role with Glooko.
“We’re thrilled to have Mark join our executive leadership team at Glooko and bring the depth of experience he has in patient care as well as medical research and education,” said Russ Johannesson, CEO of Glooko. “This background combined with his expertise in turning data and analytics into practical insights for treating people with diabetes will be a significant advantage for us, especially as he provides leadership in the development of our future product portfolio and adds his perspective as clinician and investigator to our research efforts.”
Regularly seeking to incorporate effective innovations that will enhance the care of his pediatric diabetes patients, Dr. Clements is also a clinical researcher of new diabetes treatments and technologies, having served as a principal investigator or co-investigator in more than 30 clinical studies and patient registries.
One of his key interests is in applying analytics to the data people with diabetes collect on their various diabetes or biometric devices. He’s particularly interested in how persons with diabetes can safely and securely share their own health-related data with their healthcare providers. He is also interested in how new analytic methods and new data types can help people and their healthcare providers work together to make adjustments in their daily self-management that will lead to better glucose control
“With diabetes technology today, the person with diabetes is able to accumulate enormous amounts of data about his or her diabetes and share it safely with healthcare professionals, and that ability is expanding rapidly,” said Dr. Clements. “That can provide a huge advantage in helping patients be more effective in managing their diabetes, but only if we provide tools that can help them see their data in the form of practical insights that they and their clinicians can use to effectively guide diabetes management. As the clear leader and a trusted partner in
diabetes data management, Glooko is in a unique position to forge the path toward keeping data private and secure while making it usable and practical for patients and their providers, and I’m excited to be joining the organization in leading that effort.”
Consistent with his research and leadership experience as well as his desire to find effective treatments for children with diabetes, Dr. Clements has also served as Pediatric Chair of the T1D Exchange Clinic Registry of the T1D Exchange, a nonprofit research and collaboration organization dedicated to accelerating novel therapies to improve the care of people living with Type 1 diabetes.
Dr. Clements has published extensively in peer-reviewed medical journals and is sought after as a speaker, particularly on the topic of diabetes analytics and insights.
He earned his medical degree and a PhD in developmental neuroscience from Washington University Medical School in St. Louis, and he completed a residency in pediatrics and a fellowship in pediatric endocrinology at the University of Missouri-Kansas City School of Medicine and Children’s Mercy Hospital.
Dr. Clements is board certified in pediatric endocrinology by the American Board of Pediatrics and is a fellow of the American Academy of Pediatrics (FAAP). He is also recognized as a certified principal investigator (CPI) by the Association of Clinical Research Professionals.
About Glooko
Glooko’s universal diabetes software products provide insights to improve outcomes for people with diabetes and their care teams. The Glooko product suite contains the Glooko and diasend® diabetes management solutions, which integrate with many of the leading EHR systems used today. Both systems synchronize data from more than 190 diabetes devices and fitness and activity trackers, and they deliver integrated, timely and useful patient data, including glucose levels, blood pressure, weight, and food, insulin and medication intake. Trusted by the world’s leaders in diabetes care, our solutions cover more than 2.2 million people with diabetes and are used in 9,000 clinic locations in 23 countries across 15 languages. Learn more by visiting www.glooko.com.
Media Contact:
Holly McGarraugh 510-282-2852
Free app enables effective self-management plus the ability for providers to remotely monitor their diabetes populations
March 5, 2019, Mountain View, CA. Glooko, the leader in diabetes data management, announced today its mobile app (available for Android and iOS) is now free* for any person with diabetes. Previously, there was a subscription fee for individuals not sponsored through their provider, health plan, or employer. The mobile app can help users effectively self-manage their condition through glucose tracking, insights delivery and by correlating food, exercise and medication data to create actionable insights. For healthcare providers who use Glooko for remote monitoring, their entire patient population now will be available for them to provide this service. Glooko remote monitoring programs have been demonstrated to help participants improve outcomes, including improving average blood glucose by 12% and reducing the occurrence of hyperglycemia by 15%**; this change allows a broader population to experience these clinical benefits.
Remote monitoring also offers providers the ability to have efficient in-clinic appointments, as patients can sync their device data at home rather than doing so in the office, as well as access new revenue streams via newly available CPT codes for remote patient monitoring. These codes provide reimbursement for key tasks required to remotely monitor patients, including training patients, collecting and monitoring remotely synced data, and communicating with patients about changes to their treatment plan based on the data they sync remotely.
“Glooko strives to improve the lives of people with diabetes by providing actionable insights to inform care decisions,” said Russ Johannesson, CEO of Glooko. “I am thrilled we are removing the subscription fee for users of the mobile app – this will allow anyone who wants to use Glooko for self-management to be able to do so. I am also excited about the ability for providers to remotely monitor larger patient populations. Diabetes is a very complicated, data-intensive condition; more frequent support for patients is critical in helping them better manage their diabetes.”
All features of the Glooko mobile app will be available in the free version, including the ability to sync data from compatible blood glucose meters, insulin pumps, continuous glucose monitors, and fitness trackers, the ability to log food (including via the recently released barcode scanner), medication, and activity, access to interactive charts and graphs, and the ability to easily send reports to providers and care teams. Glooko also announced today the support for the first implantable long term glucose sensor, the Senseonics Eversense® Continuous Glucose Monitoring System (CGM), available in the free app. Users of the Eversense CGM simply need to connect their Eversense account to Glooko, and their Eversense data will be available along with blood glucose, insulin, food, and any other information logged.
*one-time hardware costs may apply
**improvement after three months for users in Glooko remote monitoring programs with coaching
Media contact:
Jennivine Lee Simon
[email protected]
About Glooko
Glooko’s universal diabetes software products provide insights to improve outcomes for people with diabetes and their care teams. The Glooko product suite contains the diasend® and Glooko diabetes management solutions, which integrate with many of the leading EHR systems used today. Both systems sync data from 190+ of the world’s most popular diabetes devices, major fitness and activity trackers and supplies personalized, timely patient data such as glucose level, food, insulin, medications, blood pressure and weight data. Trusted by the world’s leaders in diabetes care, our solutions cover more than 2.2 million people with diabetes and are used in 9,000 clinic locations in 23 countries across 15 languages. Learn more by visiting www.glooko.com.
Gothenburg, Sweden / Mountain View, CA, 19 February 2019 – Glooko, the leader in diabetes data management, is gearing up for the ATTD trade show (Advanced Technologies & Treatment for Diabetes) with several exciting announcements: the launch of Novo Nordisk connected insulin pens on the diasend® platform, compatibility with the Dexcom G6 continuous glucose monitor – and the release of its Annual Diabetes Report, which will be presented to the audience in Berlin later this week.
In early 2017, Glooko and Novo Nordisk teamed up for the initial pilot of the next generation insulin pens. Enrolled patients used Novo Nordisk’s new connected devices as part of their treatment, and shared captured insulin data with their doctors via the diasend® by Glooko in-clinic solution. With diasend®, doctors were able to see and advise patients based on recorded insulin dose data from connected Novo Nordisk pens without having to invest additional time. Now, to raise the bar for patient convenience even further, Glooko is launching the ability to also upload pen data remotely – straight from any near field communication (NFC) equipped Android phone running the diasend® Mobile App.
“Our partnership with Glooko is already helping healthcare professionals to better understand their patients’ diabetes management,” says Søren Smed Østergaard, Vice President of Digital Health at Novo Nordisk. “By integrating our connected, durable insulin pens with the diasend® Mobile App, we will soon help people manage their disease and access healthcare when they need it.”
“This is a big step in using data to improve diabetes management. Until now, data from insulin pens was self-reported and subject to error, or often simply not captured. Our partnership with Novo Nordisk enables this insulin data to be seamlessly synced to diasend®, where patients and providers can easily see the data correlated with glucose levels, activity information and more. This allows much more informed conversations and decisions about the insulin regimen as well as other aspects of the treatment plan” says Russ Johannesson, CEO of Glooko.
The launch of Novo Nordisk’s first connected insulin pens, NovoPen® 6 and NovoPen Echo® Plus, will commence in early 2019. Any health care provider using diasend® in the clinic, and any patient using the diasend® Mobile App on an NFC equipped Android phone, will be able to sync data from the pens.
In addition, Glooko is also rolling out compatibility with Dexcom’s popular G6 continuous glucose monitoring system for the diasend® solution. This means that PWDs can either upload data to diasend® when visiting their health care provider, via the in-clinic upload solution*, or sync continuously by setting up a cloud-to-cloud connection with their Dexcom CLARITY account. The latter is now also possible through the Glooko product, offered in the US.
Lastly, Glooko is presenting its Annual Diabetes Report at the ATTD trade show in Berlin later this week. With a sum total of almost 15 billion data points, readers will once again get to know which country has the lowest average BG value, countries with the highest frequency of hypoglycemia and which day was the best (most time in range) day for people living with diabetes. Glooko also shares real world examples of how the insights it provides improves outcomes for diabetes populations – on average, populations using the Glooko product experience a 12% improvement in blood glucose within three months. For all of that, and more, check out the full report HERE.
* Country availability may vary.
About Glooko
Glooko’s universal diabetes software products provide insights to improve outcomes for people with diabetes (PWDs) and their care teams. The Glooko product suite contains the diasend® and Glooko diabetes management solutions, which integrate with many of the leading EHR systems used today. Both systems sync data from 190+ of the world’s most popular diabetes devices, major fitness and activity trackers and supplies personalized, timely patient data such as glucose level, food, insulin, medications, blood pressure and weight data. Trusted by the world’s leaders in diabetes care, our solutions cover more than 2.2 million PWDs and are used in 9,000 clinic locations in 23 countries across 15 languages. Learn more by visiting www.glooko.com.
Press contact
Sebastian Persson
Marketing Director EMEA/APAC
+46 701 46 10 10
Glooko now boasts 9,000 clinical locations and 2.2M patients on its platform
January 24, 2019, Mountain View, CA and Gothenburg, Sweden. Glooko, the leader in diabetes data management, had a successful 2018 fueled by strong growth in health system customers, international expansion, and new partnerships. The recent success creates a strong foundation for continued momentum in 2019. During 2018, Glooko added over two thousand health systems and clinic locations across 23 countries, and achieved near 100% specialty clinic penetration in Sweden and England. Health systems use Glooko’s award winning diabetes data management solution to provide both in-clinic andremote patient support; Glooko now has over 2.2M patients on its platform. Recent studies have demonstrated that Glooko use can drive better outcomes such as improving average blood glucose and lowering the risk for hyperglycemia1.
Said Dr. Luigi Meneghini, Executive Director of Parkland Health & Hospital System Global Diabetes Program, “We implemented the Glooko platform to streamline downloading data from monitoring devices in the Diabetes & Foot Wound Clinic at Parkland, and importantly, to have that information easily available to providers and other healthcare professionals. We have improved our workflows around the use of patient self-monitored blood glucose (SMBG) data, reduced the need for paper logbooks and enhanced the safeguard of that data. Our providers appreciate the standard interface, data reports and analyses and the ability to share this information with patients during their visit. This is a tool that facilitates the use of SMBG data for the management of hyperglycemia at the point of care and increases the value of that data.”
Glooko continues to add blood glucose meters, insulin pumps, continuous glucose monitors, and other diabetes and health devices to its platform, and in 2018, has entered into partnerships with close to a dozen additional medical device and pharmaceutical companies to support their products. Glooko now syncs data with over 190 devices globally, including the Omnipod Dash, Dexcom G6, and new innovations such as smart insulin pens, implantable sensors, and patch pumps once they are commercially available. Glooko has also expanded strategic relationships with partners such asNovo Nordisk and Insulet to support new product innovations and expand access to Glooko in new geographies. With over 12 billion data points, the Glooko database is one of the largest in the diabetes industry and generates powerful insights to help providers and people with diabetes make treatment decisions.
“I’m extremely proud of the success we’ve achieved in 2018, and look forward to accelerating our growth this year,” said Russ Johannesson, CEO of Glooko. “We continue to invest in our capabilities to provide diabetes insights and decision support to providers and people with diabetes and are excited to introduce enhanced offerings that aim to improve care and lower costs.”
1. Digital Diabetes Management Application Improves Glycemic Outcomes in People With Type 1 and Type 2 Diabetes, Journal of Diabetes Science and Technology, 2017